InsiderTrades.com logo
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

BIT Insider Trading

Insider Ownership Percentage: 14.13%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Biotron Insider Trading History Chart

This chart shows the insider buying and selling history at Biotron by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biotron Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for BIT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

Biotron Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/25/2022Michelle MillerInsiderIssued300,000A$0.03A$9,000.00
See Full Table
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for Biotron (ASX:BIT)

Biotron logo
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Read More on Biotron

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

1,032,419 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

5.08%

Beta

N/A

Who are the company insiders with the largest holdings of Biotron?

Biotron's top insider investors include:
  1. Michelle Miller (Insider)
Learn More about top insider investors at Biotron.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.